Rankings
Pricing
Log In
Free Trial
US-listed companies
Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc.
ARQT
Market cap
$970.07M
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2023
Net loss
-262
Depreciation
1
Non-cash lease expense
0
Amortization of intangible assets
1
Net amortization/accretion on marketable securities
7
Accretion Expense
4
Stock-based compensation
39
Change in fair value of embedded derivative instrument
-1
Accounts receivable, net
17
Inventories
6
Prepaid expenses and other current assets
9
Accounts payable
3
Accrued liabilities
6
Operating lease liabilities
-1
Net cash used in operating activities
-247
Purchases of marketable securities
226
Proceeds from maturities of marketable securities
407
Purchases of property and equipment
0
Net cash provided by (used in) investing activities
180
Proceeds from Stock Options Exercised
1
Proceeds from issuance of shares under ATM, net of issuance costs
3
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs
96
Proceeds from issuance of common stock for ESPP
1
Net cash provided by financing activities
101
Effect of exchange rate changes on cash
-0
Net increase (decrease) in cash, cash equivalents and restricted cash
34
Interest expense paid in cash
25